In the context of SMA, studies on mouse models have demonstrated that PMOs can significantly increase SMN2 levels and improve survival rates through various delivery routes, including intrathecal and intravenous injections, although the superiority of these delivery routes remains debated. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.